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Background: Human epididymis protein 4 (HE4) also referred to as whey acidic protein (WAP) is a
promising and heavily studied biomarker for ovarian cancer. A systematic review of studies evaluating the
prognostic significance of pretreatment HE4 in women with epithelial ovarian cancer was performed.
Methods: An exhaustive search of medical literature using Medline-OVID, Web of Science, CINAHL and
Google Scholar was performed. The search was limited to year 2000 to 2013, human subjects and the English
language. Each study was appraised and quality was assessed using the GRADE criteria.
Results: A total of five observational studies were included. One study evaluated the prognostic value of HE4
for progression-free survival (PFS), disease-free survival (DFS) and overall survival (OS), while two studies
only evaluated for PFS. The remaining studies evaluated for both PFS and OS. Of the four studies that
evaluated for PFS, three studies showed that a higher preoperative serum HE4 level is significantly associated
with shorter PFS. However, the remaining study showed no association between preoperative serum HE4
level and PFS. The three studies that evaluated for OS, all showed significant association between high
preoperative HE4 levels and shorter OS. One study for DFS showed similar correlation of having high HE4
levels and increased frequency of relapse.
Conclusion: Based on the current analysis, HE4 can be considered a valuable biomarker in assessing the
prognosis of women with ovarian cancer prior to receiving primary treatment. This test can also help in
identifying women who will benefit with more aggressive treatment. A weak recommendation is made in the
use of HE4 test because majority of the studies had small sample sizes and were performed in single sites, thus
making it difficult to generalize the results. A large, multi-center prospective study would validate the findings
of this review.
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Abstract   
 
Background:  Human epididymis protein 4 (HE4) also referred to as whey acidic protein (WAP) 
is a promising and heavily studied biomarker for ovarian cancer. A systematic review of studies 
evaluating the prognostic significance of pretreatment HE4 in women with epithelial ovarian 
cancer was performed.  
 
Methods:  An exhaustive search of medical literature using Medline-OVID, Web of Science, 
CINAHL and Google Scholar was performed.  The search was limited to year 2000 to 2013, 
human subjects and the English language.  Each study was appraised and quality was assessed 
using the GRADE criteria.  
 
Results:  A total of five observational studies were included.  One study evaluated the prognostic 
value of HE4 for progression-free survival (PFS), disease-free survival (DFS) and overall 
survival (OS), while two studies only evaluated for PFS. The remaining studies evaluated for 
both PFS and OS.  Of the four studies that evaluated for PFS, three studies showed that a higher 
preoperative serum HE4 level is significantly associated with shorter PFS.  However, the 
remaining study showed no association between preoperative serum HE4 level and PFS.  The 
three studies that evaluated for OS, all showed significant association between high preoperative 
HE4 levels and shorter OS. One study for DFS showed similar correlation of having high HE4 
levels and increased frequency of relapse.   
 
Conclusion:  Based on the current analysis, HE4 can be considered a valuable biomarker in 
assessing the prognosis of women with ovarian cancer prior to receiving primary treatment.  This 
test can also help in identifying women who will benefit with more aggressive treatment.  A 
weak recommendation is made in the use of HE4 test because majority of the studies had small 
sample sizes and were performed in single sites, thus making it difficult to generalize the results.  
A large, multi-center prospective study would validate the findings of this review.  
 
Keywords:  Ovarian cancer, Human epididymis 4, prognosis, survival 
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Human Epididymis Protein 4: A Prognostic Tool for Epithelial Ovarian 
Cancer 
 
BACKGROUND 
 Ovarian cancer is the most lethal of all the gynecological cancers and is the fourth most 
common cause of death in women with cancer.1  In the United States, about 20 000 women are 
diagnosed with ovarian cancer each year and 14 000 women have already died from the disease.2  
If detected in the early stages (I-II), the five year survival rate is 70 to 90% and then drops to < 
40% if detected in the later stages (III-IV).3  Along with early detection, it is important to have a 
good prognostic tool to identify those women in need of a rigorous treatment regimen and to 
monitor treatment response.  Currently, the International Federation of Gynecology and 
Obstetrics (FIGO) stages and clinicopathologic parameters are being used to assess prognosis in 
epithelial ovarian cancer.4   
 The CA-125 antigen has been the gold standard biomarker for ovarian cancer. Elevated 
serum CA-125 levels were detected in women with borderline and malignant ovarian cancer; 
however elevated levels were also detected in benign lesions such as endometriosis, uterine 
myomas, acute and chronic salpingitis and pelvic inflammatory disease.5  Several studies have 
tested the prognostic value of CA-125 prior to therapy and after primary treatment.  They found 
that high CA-125 levels after treatment and surgery to be a significant prognostic factor and that 
an increase in CA-125 level is associated with 15% increase in risk of progression for women 
with a stage of FIGO III.6, 7  A meta-analysis showed an inverse relationship between 
prechemotherapy serum CA-125 levels and survival; however, they also found that CA-125 
levels when taken at time of diagnosis to have limited prognostic value.8  The use of CA-125 for 
monitoring treatment response is also considered to be investigational since there has been no 
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evidence linking improved quality of life and survival with re-institution of therapy in 
asymptomatic patients with rising CA-125 levels.9 
 Human epididymis protein 4 (HE4) also referred to as whey acidic protein (WAP) has 
been heavily studied for its diagnostic and screening ability in ovarian cancer.10, 11  HE4 contains 
two whey acidic protein domains and a four-disulfide core with eight cysteine residues.12  This 
protein is highly expressed in the epididymis, female reproductive tract and respiratory 
epithelium.  It is strictly expressed in normal human tissues; however, HE4 was found to be 
overexpressed in serous and endometrioid ovarian carcinomas.13  Unlike CA-125, HE4 levels 
were less frequently elevated in patients with benign disease, fibroids or pelvic inflammatory 
disease and its serum levels were higher in the early disease stages (FIGO I-II).14, 15  Anastasi et 
al16 found that HE4 serum levels rose earlier than CA-125 by five to eight months and that the 
increase in serum HE4 coincided with the recurrence and worsening of the disease.  Two meta-
analyses10, 11  on studies evaluating the diagnostic ability of HE4 were performed and both 
analyses found HE4 to have better sensitivity and specificity for diagnosis of ovarian cancer.  
 The prognostic value of HE4 in ovarian cancer has been unclear.  It is the goal of this 
review to evaluate the available studies about the prognostic ability of HE4 in women with 
epithelial ovarian cancer.  Currently, prognosis is based on tumor stage (i.e. FIGO stage) and 
clinicopathologies (e.g. age, tumor grade, presence of ascites, lymph node metastases, etc.).  
Since most ovarian cancers are not diagnosed until the later stages, there is a need for a tumor 
marker that can help identify women who will benefit in receiving more aggressive adjuvant 
chemotherapy.  Whether as an individual marker or used in combination with CA-125, the ability 
to ascertain the prognosis of a patient based on biomarker levels can help increase the patients’ 
 - 9 - Revised 07Dec2009 
overall survival and increase their quality of life.  Is there a prognostic value in the pre-treatment 
serum level of HE4 in women with epithelial ovarian cancer? 
 
METHODS  
 Using MEDLINE, CINAHL, Web of Science and Google Scholar, an extensive literary 
search was performed using the following keywords: “ovarian neoplasm,” “prognosis,” 
“morbidity,” “whey acidic protein,” “epididymal secretory protein” and “HE4.” Bibliographies 
of selected articles were searched for relevant articles.  Inclusion criteria included studies that 
measured the prognostic ability of HE4 in ovarian cancer as one of the primary outcomes, on 
patients with a new diagnosis of epithelial ovarian cancer and on blood samples obtained prior to 
surgery and chemotherapy.   The search was limited to year 2000 to 2013.  Relevant articles 
were appraised and assessed by GRADE criteria.17   
 
RESULTS 
 The initial search resulted in 685 articles for review.  The articles were screened for 
primary data and were limited to humans and the English language.  Five articles18-22 met the 
inclusion criteria and their general characteristics are shown in Table 1. The GRADE17 
assessment of the studies is shown in Table 2.  
 
Paek et al Study 
 This prospective study17 evaluated the prognostic significance of serum HE4  in women 
with epithelial ovarian cancer (EOC).  The primary outcome of the study was to determine the 
correlation between serum HE4 levels and survival outcomes in women with EOC.  The 
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secondary outcome was to determine the prognostic value of HE4 in patients with EOC treated 
with combination of platinum-based chemotherapy and taxane.18   
 The study included 78 women with pelvic masses scheduled to undergo surgery.  Forty-
five of the 78 women had full surgical staging or tumor debulking based on the diagnosis of 
ovarian malignancy and received post-operative taxane and platinum based chemotherapy.  
However, one patient with stage IA malignant disease received 6 cycles of paclitaxel 175 mg/m2 
and carboplatin at area under the curve of 5.  All patients gave informed consent prior to blood 
collection and surgery.  Blood samples were collected preoperatively.  Ovarian tissues were 
sampled during surgery and examined by a gynecologic pathologist.  Patient age, menopausal 
status, Gynecologic Oncology Group (GOG) performance status, FIGO stage, lymph node 
metastases and tumor grade were baseline characteristics evaluated for each patient.18    
 Serum samples were used to measure HE4 and CA-125 levels using an established 
ELISA kit (Fujirebio Diagnostics, Malvern, PA, USA).  Assays were run following 
manufacturer’s instructions and controls were determined to be within manufacturer standards.  
The authors used the normal HE4 definition established by Moore et al23 which is a serum level 
equal to or below 70 pM.  While CA-125 level of equal to or below 35 U/mL was considered 
normal.  This level was consistent with clinical practice use.  Statistical analyses were two-tailed 
and p values <.05 were considered to be statistically significant.18  
 Of the 78 patients in the study: 45 had EOC, 21 with benign ovarian tumor and 12 with 
normal ovarian tissue.  The authors found that the median age of patients with EOC was 
significantly higher than patients without cancer (51.1 yrs versus 46.7 yrs, respectively, p = 
0.018), but there were no difference between the number of menopausal women with EOC and 
those without.   Follow-up for 45 patients with EOC had a median time of 35.1 months (range 1-
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55).   The authors found that patients with elevated HE4 levels (n = 45) had a median 
progression-free survival (PFS) of 21.7 months (95% Confidence Interval [CI], 17.3-26.0 
months) and a three-year PFS rate of 29%.  However, patients with normal serum HE4 levels (n 
= 33) had median PFS of 24.6 months (95% CI, 17.5-31.8 months) and a three-year PFS rate of 
50%.  Patients with stage IIIC and IV (n = 35) and elevated serum HE4 levels, had median PFS 
of 20.1 months (95% CI, 15.7-24.6 months) and a three-year PFS rate of 25%, while those with 
normal serum HE4 levels had median PFS of 24.2 months (95% CI, 13.9-34.6 months) and a 
three-year PFS rate of 57.1%.  Multivariate analysis showed that elevated serum HE4 levels to 
be the only significant prognostic factor for PFS in patients with EOC stages IIIC and IV.  The 
authors also found elevated levels of serum HE4 to be an independent predictor of PFS in 
patients with advanced stage EOC (hazard ratio [HR] = 2.24; 95% CI, 1.14-6.84; p = 0.048).18   
 Though elevated serum HE4 levels were associated with advanced disease, there was no 
correlation with tumor grade, lymph node metastases and residual tumor size.  The study showed 
that the serous type of EOC is associated with high serum HE4 levels.  The limitations of the 
study included insufficient sample size and lack of randomization when choosing patient 
population.  The number of patients with EOC (n = 45) was higher than the number of patients in 
the non-cancer group (n = 33) and patients with benign ovarian tumor (n = 21), thus lacking 
ability to detect statistically significant difference between the groups.18   
 
Kong et al Study 
 This retrospective observational study18 assessed whether pretreatment levels of HE4 is 
an independent prognostic factor in patients with primary ovarian cancer.  In addition, the study 
also evaluated correlation between HE4 levels and other established prognostic factors. 19  
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 Prior to surgery, blood samples were obtained from patients with primary EOC and were 
stored in the Tumor Bank National Cancer Center of Korea.  Eighty blood samples were 
obtained from the tumor bank and their corresponding medical records were reviewed by the 
authors.  The inclusion criterion was mainly composed of patients with primary EOC.  All of the 
patients in the study underwent comprehensive surgical staging and multiple peritoneal biopsies.  
Surgical staging included total hysterectomy, bilateral oophorectomy, peritoneal washing, 
omentectomy and pelvic/para-aortic nodal biopsy.  Extensive upper abdominal surgical 
procedures were performed as necessary to achieve complete cytoreduction.  Complete 
cytoreduction was defined as no macroscopic residual tumor, while optimal cytoreduction was 
defined as a residual tumor size < 1 cm.  With the exception of patients with stage Ia or Ib 
disease, all of the patients received standard chemotherapy with carboplatin and paclitaxel after 
cytoreduction surgery.19  
 Assay kits from Fujirebio Diagnostics were used to assess the serum concentrations of 
CA-125 and HE4.  The assay technicians followed instructions provided by the manufacturer.  
Appropriate controls were chosen and were determined to be within the ranges provided by the 
manufacturer.19   
 Of the 80 patients diagnosed with EOC, 70 (87.5%) had FIGO stage III-IV disease with 
the following histologic distribution: 63 serious, 6 endometrioid, 6 clear cell and 5 mucinous 
tumors.  The authors’ analysis of association between PFS and serum HE4 levels showed a 
median PFS of 19.8 months (95% CI, 15.2 – 29.5).  The logarithm value of HE4 levels showed 
significant correlation with PFS  (HR = 1.62; 95% CI, 1.16 – 2.24, p = 0.004) while none with 
serum CA-125 (HR = 1.13; 95% CI, 0.99 – 1.30, p = 0.077).  In addition to HE4 serum levels as 
a prognostic factor in patients with EOC, they also found the patient’s age at diagnosis, advanced 
 - 13 - Revised 07Dec2009 
tumor stage (FIGO III-IV), histologic grade III and non-serous histologic type to be prognostic 
factors as well.  Dividing patients according to their HE4 serum levels showed worse PFS in 
patients with higher serum HE4 levels (p = 0.017) while doing the same analysis with CA-125 
did not show significant correlation with PFS (p = 0.077).  Lastly, the authors did a multivariate 
analysis that included variables with p < 0.3 from their univariate analysis.  The variables chosen 
were patients’ age, stage, tumor histology, residual tumor size, serum HE4 levels and CA-125 
levels.  For the multivariate Cox’s proportional hazard model, the authors used a stepwise 
analysis with a cutoff value of p = 0.25 which resulted in the exclusion of tumor histologic 
subtypes, residual tumor size and serum CA-125 levels from the analysis.  The authors decided 
to include residual tumor size in the Cox’s proportional hazard model analysis due to its well-
established prognostic value in EOC.  The authors also believed that tumor size was excluded in 
the stepwise analysis because of the low incidence of suboptimal surgeries in the institution at 
which the research was performed.  With this adjustment, the authors found that HE4 serum 
level maintained its prognostic value (HR = 1.47; 95% CI, 1.02 – 2.10, p = 0.036).  The cross-
validation of the analysis showed pretreatment serum HE4 level as a significant predictor of poor 
outcome (HR = 1.47; 95% CI, 1.09 – 1.97, p = 0.012).  It also showed that pretreatment HE4 
levels to be significantly correlated with PFS (p = 0.029) in patients with advanced tumor stage 
(FIGO III-IV).  However, they were unable to show correlation between residual tumor size and 
PFS (p = 0.32).19   
 The authors observed that high serum HE4 levels to be associated with histologic subtype 
and higher tumor grade.  However, the authors were unable to find association between serum 
HE4 levels and aggressive tumor biology which is a clearer indicator of prognosis for ovarian 
cancer.  Limitations of the study included lack of external validation, small sample size, 
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retrospective nature of the study, lack of control subjects and lack of blinding of those 
performing the analyses.19   
 
Bandiera et al Study 
 Bandiera and colleagues19 assessed the diagnostic and prognostic value of serum HE4 
and Risk for Ovarian Malignancy Algorithm (ROMA) in EOC.  The authors wanted to evaluate 
the role of HE4 and ROMA in predicting OS, DFS and PFS in patients with EOC compared to 
an established prognostic factor, CA-125.20   
 The study population had a total of 419 patients that were referred to the Gynaecologic 
Oncology Department of the University of Brescia from 2003 to 2010. Patients with past or 
concomitant history of malignancy were excluded from the study.  Patients were divided into 
cohorts according to menopausal status and were balanced in regards to age and number of 
participants.  Each cohort were also balanced with healthy controls (n = 140).  The authors 
defined women to be post-menopausal if their last menstrual period was 12 months prior to the 
blood collection.  The medical records of patients with EOC were reviewed at time of diagnosis, 
treatment and follow-up to attain all clinical and pathologic features of the disease.  Patients 
diagnosed with low potential malignancy tumor were excluded from the study.  Patients with 
EOC received the standard treatment of complete pelvic surgery with cytoreductive surgery for 
advanced stages, and platinum-based chemotherapy.  Of the 114 patients with EOC, 98 patients 
were included in the survival analysis.  Patients were excluded from the analysis if they refused 
chemotherapy, if they were not eligible for primary surgery and if follow-up was incomplete.  
Patient follow-up was from date of surgery until death or November 30, 2010 with median 
follow-up time of 19.5 months (range 1 – 85 months).20   
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 Blood samples were obtained prior to surgery or chemotherapeutic treatment.  Serum 
levels of CA-125 and HE4 were measured using microassays and read by ARCHITECT by 
Abbott Diagnostics.  Normal range HE4 were provided by the manufacturer as ≤ 70 pmol/L for 
premenopausal state and ≤ 140 pmol/L in menopausal state.  The authors used cancer relapse, 
cancer progression and cancer-related death as endpoints to calculate DFS, PFS and OS, 
respectively.  DFS was defined as the interval between surgery date and date of identification of 
disease recurrence.  PFS was the time interval between date of surgery and date when 
progressive disease is identified such that the disease is untreatable with curative intent.  Finally, 
OS was the time interval between surgery date and date of death.20   
 Using univariate analysis, the authors observed FIGO stage, residual tumor after 
cytoreductive surgery, histologic subtype, presence of ascites, positive cytology, lymph node 
involvement and age were all significantly associated with OS, DFS and PFS.  Elevated levels of 
CA-125, HE4 and ROMA were associated with shorter OS, DFS and PFS (all p < 0.028).   Using 
multivariate analysis, biomarker effects were adjusted for FIGO stage, residual tumor and 
histologic subtype, all of which are established prognostic factors for ovarian cancer.  The 
analysis showed residual tumor to be an independent prognostic factor for DFS (HR = 3.05; 95% 
CI, 1.29 – 7.21; p = 0.011) and for PFS (HR = 3.00; 95% CI, 1.15 – 7.83; p = 0.025) compared to 
other established prognostic factors.  Among the three biomarkers, HE4 and ROMA were found 
to be independent prognostic factors for OS, DFS and PFS with both having p = < 0.039.20   
 The study implicates that higher levels of HE4 and ROMA as possible prognostic factors 
in EOC that will help identify a subgroup of patients with poor survival and higher risk of death, 
thus requiring more aggressive adjuvant therapy.  Limitations of the study included lack of 
blinding of those performing data analysis, blinding of the technicians assessing serum levels of 
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CA-125 and HE4 and possible selection bias since the study was performed in a single 
institution.20    
 
Kalapotharakos et al Study 
 This prospective study20 aimed to assess the prognostic value of preoperative levels of 
HE4 in overall survival (OS) of patients with ovarian cancer.  The secondary outcome of the 
study is to validate the diagnostic ability of both HE4 and ROMA algorithm in differentiating 
malignant from benign ovarian tumors.21   
 The study population consisted of women who were referred to the Department of 
Obstetrics and Gynecology between 1993 and 2009 for primary surgery of adnexal masses.  
Blood samples were obtained from 312 patients prior to surgery.  Patient diagnoses were verified 
by tumor histopathology.  For malignant cases, histopathological grade and disease stage (FIGO) 
were obtained and those with invasive cancer were given postoperative adjuvant chemotherapy.  
Patients with stage Ic or higher received platinum-based chemotherapy as monotherapy or 
combined with paclitaxel.  Patient survival status was obtained from the Swedish Population 
Registry on September 17, 2010.  The median follow-up time after surgery for patients with 
invasive tumors was 31 months (range 0.2 – 203 months) and 90 months (range 19 – 203 
months) for living patients.21   
 CA-125 plasma was assayed using a commercially available kit from Roche and was 
performed according to manufacturer instructions.  The HE4 levels were assayed using HE4 EIA 
kit from Fujirebio Diagnostics.  The technicians who performed the assays were blinded to both 
the clinical and histopathologic status of the patients.21   
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 The authors of the study observed that patients with invasive ovarian cancer (FIGO stage 
III-IV) had significantly higher preoperative serum HE4 levels (median 569 pM) compared to 
those with FIGO stage I or II disease (median 101 pM, p < 0.001).  They also observed HE4 
preoperative levels were significantly higher for patients with histologic grade 3 tumors (median 
588 pM) compared to patients with grade 1 or 2 tumors (median 153 pM, p < 0.001).  Using 
univariate Cox regression analyses, high levels of HE4, CA-125, increased age, advanced-stage 
of disease 2-4, histological grade 3 and non-optimal tumor debulking at primary surgery were all 
significantly associated with shorter OS.  In comparing HE4 and serous cancer, higher HE4 
levels prior to surgery were significantly associated with shortened OS (HR = 3.7; 95% CI, 1.6 – 
8.9, p = 0.003) while higher HE4 levels did not predict overall survival in non-serous tumors 
(HR = 0.8; 95% CI, 0.3 – 2.7, p = 0.7).  Lastly, a multivariate analysis of covariates with CA-125 
and HE4 showed higher levels of HE4 as an independent prognostic marker for worse prognosis 
(HR 2.02; 95% CI, 1.1 – 3.8, p = 0.02).21  
 The study showed that high preoperative levels of HE4 as an independent prognostic 
maker for poor OS in ovarian cancer.  The authors were also able to show that preoperative HE4 
levels were correlated with high tumor grade and serous histology and worse prognosis in 
women with high HE4 levels with serous ovarian cancer.  Since the study was observational in 
nature and was performed in a single institution, it has a higher susceptibility to selection bias.21 
   
Trudel et al Study 
 In this retrospective cohort study, Trudel and colleagues21 evaluated the prognostic value 
of plasma HE4 levels in overall survival and progression in women with ovarian cancer.  The 
primary endpoint of the study was to evaluate whether higher preoperative HE4 levels were 
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associated with lower OS while the secondary endpoint was to assess whether preoperative 
levels of HE4 were associated with the first progression of ovarian cancer.22   
 The patient population was composed of women with ovarian cancer who underwent 
primary cytoreductive surgery between January 1, 1998 and December 31, 2006 at a tertiary care 
center for ovarian cancer in Canada (L-Hotel-Dieu de Quebec of the Centre Hospitalier 
Universitaire de Quebec [CHUQ]).  Study inclusion criteria included diagnosis of EOC of any 
FIGO stage and debulking surgery complemented with adjuvant chemotherapy.  Patients who 
received neoadjuvant therapy were excluded from the study since neoadjuvant therapy affects the 
assessment of FIGO stage, tumor type and grade.  The authors reviewed the patients’ medical 
records and collected the following information: age, FIGO stage, histology, grade, preoperative 
CA-125 level and treatment modalities at time of cytoreductive surgery.  Both histology and 
grade of tumors were reviewed by a senior pathologist who was blinded to the prognosis and 
clinical information of the patients.  Follow-up data were collected from CHUQ medical files 
and other hospitals and was regularly updated until June 2012.  The guidelines of the 
Gynecology Cancer Intergroup (GCIG) were used to evaluate disease progression after first-line 
chemotherapy treatment.  The authors used either the RECIST or CA-125 criteria to document 
progression and if progression was documented by both criteria, the earlier of the two dates was 
then used.  The Quebec health insurance identifier was used to obtain the date and cause of 
death.22   
 Prior to surgery, blood was drawn from each patient.  Plasma HE4 levels were measured 
using Abbott’s ACHITECT assay and from the same sample, CA-125 levels were measured 
using a microparticle enzyme immunoassay also by Abbott. The assay technician who performed 
the HE4 analyses was blinded to both the women’s outcomes and other clinical information.22   
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 The 5-year PFS was 32% (95% CI, 25% - 40%) and 5-year OS was 51% (95% CI, 43% - 
60%) for the cohort.  The authors observed that the plasma levels of HE4 significantly increased 
with age, serous tumor, grade of tumor and pre-operative CA-125 levels.  The levels of HE4 also 
increased with FIGO stages and amount of residual tumor, though both were strongly associated 
with the study population.  Using the Kaplan Meier curves and log –rank tests, it was determined 
that high preoperative HE4 levels were significantly associated with mortality (HR = 2.17; 95% 
CI, 1.42 – 3.32) and progression (HR = 1.81; 95% CI, 1.21 – 2.72).  Multivariate analyses of the 
standard prognostic factors of ovarian cancer showed FIGO stage as the only factor statistically 
associated with death and progression.  The authors then used the FIGO stage as a base model 
for OS and PFS while expanded models included HE4 levels.  Comparison of the two models 
showed that preoperative HE4 levels added additional prognostic information for OS (LR test = 
5.49, df = 1, p = 0.019).   HE4 levels were then adjusted for FIGO stage and showed that higher 
HE4 levels remained significantly associated with death (HR = 1.67; 95% CI, 1.08 – 2.59) and 
an independent predictor of overall survival. Similar results were obtained when multivariate 
analyses including FIGO stage and grade in women with serous carcinoma (HR = 1.57, p = 
0.05).  However, when baseline model was compared to expanded model for PFS, preoperative 
HE4 levels did not significantly improve prognostic information for PFS (LR test = 1.70, df = 1, 
p = 0.19).22 
 Trudel et al21 was able to show that preoperative HE4 levels were associated with all 
standard prognostic factors of EOC.  The study showed high preoperative plasma HE4 to be an 
independent prognostic factor of death but not of progression.  The same result was also found in 
the subgroup analysis of women with serous tumors.  The retrospective nature of the study and 
single-institution base of the study makes it susceptible to selection bias.  The authors also found 
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that once they took into account FIGO stages, it decreased the association between higher 
preoperative plasma HE4 and mortality, resulting in a moderate association (HR = 1.67).   
Though the value was still statistically significant, one may consider both FIGO stages and 
residual tumor size as confounding factors that may minimize the association between HE4 and 
mortality.22 
 
DISCUSSION 
 Human epididymis protein 4 (HE4) has been shown to have better specificity and 
sensitivity than the CA-125 antigen in differentiating malignant from non-malignant pelvic 
masses.  It has been approved by the FDA for use in the US to monitor disease recurrence in 
patients with ovarian cancer in 2008 and in 2011, the combination of HE4 with CA-125 known 
as Risk of Ovarian Malignancy Algorithm (ROMA) score was also approved by the FDA for the 
evaluation of malignancy likelihood in women with pelvic masses.10   
 Pretreatment levels of HE4 are a useful adjunctive prognostic tool in assessing mortality 
and disease progression in women with ovarian cancer.  Overall, the studies18-22 included in this 
review showed that high HE4 levels to be significantly associated with advanced tumor stage 
(i.e. FIGO III-IV), grade 3 tumor and serous histology.  In addition, all five studies18-22 indicated 
significant association of high pretreatment HE4 levels with the standard prognostic factors in 
ovarian cancer, thus implicating that high serum HE4 levels to be correlated with tumor 
aggressiveness.   
 In assessing progression-free survival (PFS), Paek et al,18 Kong et al19 and Bandeira et 
al20 all showed pretreatment HE4 levels to be a significant prognostic factor.  According to these 
studies, a decrease in PFS is associated with high HE4 levels.  In contrast to these studies, Trudel 
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et al22 found no association between HE4 levels and PFS. In this study, the adjustment for FIGO 
stage caused the decrease in association between HE4 levels and PFS which was not seen in the 
previous three studies.18-20  
 In addition to PFS, overall survival (OS) is another important concern for patients with 
ovarian cancer.  Bandiera et al,20  Kalapotharakos et al21 and Trudel et al22 all found that high 
pretreatment HE4 levels to be associated with decreased OS.  Unlike in PFS, adjustment for 
FIGO stage did not affect the association between HE4 levels and OS.  Lastly, Bandiera et al20 
also evaluated disease-free survival (DFS) and HE4 levels, and found that a high pretreatment 
HE4 level is significantly associated with longer DFS.  
  Moreover, Chudeka-Glaz et al24 showed that HE4 levels at time of diagnosis had no 
correlation with prognosis of complete remission; however they did find that lower HE4 levels 
correlated with a longer duration of remission.  Patients with normal HE4 levels at time of 
diagnosis relapsed less frequently as opposed to those with high HE4 levels.  They also found 
that patients who died prior to two years of diagnosis had higher HE4 levels. These findings are 
consistent with the correlation between high HE4 levels and shorter overall survival and disease 
progression.   
 The studies included in this review did utilize important methodology in measuring this 
correlation.  Bandeira et al20 used a large study population and healthy controls.  While Trudel et 
al22 blinded both the pathologist assigning the tumor stage and the assay technician from the 
patients’ clinical information and prognosis.  The lack of blinding and inconsistency with the 
results for progression-free survival resulted to a very low assessment for this outcome.  Studies 
which assessed overall survival were not downgraded and maintained its low assessment.  Since 
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Bandeira20 was the only study that assessed for disease-free survival, the assessment was 
downgraded to very low due to lack of blinding.   
 All five studies in this review were observational; hence they are more susceptible to 
selection bias.  Majority of the studies had small study population sizes which can maximize or 
minimize the results of the studies.  Lastly, most of the studies were performed in single 
institutions, thus increasing the likelihood of referral bias.  However, none of the studies were 
industry funded so publication bias is very unlikely.   
 In summary, this study results in a weak recommendation for the use of pretreatment 
HE4 levels as a prognostic tool in ovarian cancer.  Though may not be ideal as an individual test, 
pretreatment HE4 levels can be used in combination with CA-125 levels, FIGO stage and 
residual tumor size to assess the prognosis of women with ovarian cancer.   
    
CONCLUSION 
 Human epididymis protein 4 (HE4) should be considered as a valuable prognostic 
biomarker in epithelial ovarian cancer.  High HE4 levels are correlated with advanced tumor 
stage, serous histology, tumor aggressiveness and decreased overall survival.  The use of 
pretreatment HE4 levels as a prognostic tool in assessing overall survival and disease 
progression is weakly recommended.  The use of HE4 in conjunction with established ovarian 
cancer prognostic factors can be of great benefit to both the clinician and patient.  This approach 
will help identify women who may benefit with aggressive treatment which can increase their 
overall survival and improve their quality of life.  
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 Table1. Characteristics Reviewed Studies 
 
Study Study  
Design 
Blinding Healthy 
Controls 
Benign 
Disease 
Ovarian 
Cancer 
Assay 
Methods 
Cutoff 
(pM/L) 
        
Paek et al18 Prospective 
Cohort 
NO 12 21 45 ELISA 70 
Kong et al19 Retrospective 
Cohort 
NO 0 0 80 ELISA 70 
Bandiera et al20 Prospective 
Cohort  
NO 140 165 98 CMIA 70 
Kalapotharakos 
et al21 
Prospective 
Cohort 
YES 0 206 85 ELISA Median of 
405 
Trudel et al22 Retrospective 
Cohort 
YES 0 0 136 CMIA Median of 
394 
ELISA = Enzyme-linked Immunoassay;  CMIA = Chemiluminescent microparticle immunoassays 
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Table 2. Summary of Findings and GRADE Profile                                                                               
GRADE16: Grading of Recommendations, Assessment, Development and Evaluations 
aPaek at al,18 Kong et al19 and Bandeira20 all three studies had no blinding. 
bTrudel et al22 results for PFS contradicted the results of the other three studies. 
cBandeira20 no blinding in the study. 
 
Quality Assessment Summary of Findings 
 Downgrade Criteria  Number of Patients Effect Quality Importance 
No. of 
Studies 
Design Limitations Indirectness Imprecision Inconsistency 
Publication 
Bias 
Study Ovarian Cancer Benign Masses Hazard Ratio 
95% CI 
(p-value) 
 
 
Progression Free Survival 
4 4 Observational 
Serious 
limitationsa 
No serious 
indirectness 
No serious 
imprecision 
Serious 
inconsistenciesb 
No bias likely 
Paek et al18 45 33 2.24 
1.14 – 6.84   
(p <.048) 
Very Low Critical 
Kong et al19 80 0 1.47 
1.02 – 2.10   
(p <.036) 
Bandiera et a20l 98 165 2.77 
1.12 – 6.85   
(p <.028) 
Trudel et al22 136 0 1.32 
0.87 – 1.99   
(p < .190) 
Overall Survival 
3 3 Observational 
No serious 
limitations 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
No bias likely 
Bandiera et al20 98 165 3.98 
1.35 – 11.75 
(p <.012) 
Low Critical 
Kalapotharakos et 
al21 
85 206 2.02  
1.10 – 3.80   
(p <.020) 
Trudel et al22 136 0 1.67 
1.08 – 2.59   
(p < .019) 
Disease Free Survival 
1 1 Observational 
Serious 
limitationsc 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
No bias likely Bandiera et al20 98 165 2.46 
1.09 – 5.56   
(p <.011) 
Very Low Critical 
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